JUBLIA Drug Insight

“JUBLIA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about JUBLIA for Onychomycosis in the seven major markets and China. A detailed picture of the JUBLIA for Onychomycosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, Japan, and China for the study period 2019–2032 is provided in this report along with a detailed description of the JUBLIA for Onychomycosis .The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JUBLIA market forecast, analysis for Onychomycosis in the 7MM and China descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Onychomycosis.

Drug Summary

Efinaconazole 10% nail solution (JUBLIA) is a new topical triazole antifungal designed for the topical treatment of distal and lateral subungual onychomycosis. Efinaconazole has lower minimum inhibitory concentrations than terbinafine, ciclopirox, itraconazole, and amorolfine in Trichophyton rubrum, Trichophyton mentagrophytes, and Candida albicans. The solution-based formula has low surface tension and keratin binding properties that increase penetrance through the nail plate. Safety studies have shown that this formulation is not associated with atopic dermatitis or contact sensitivity. Efinaconazole 10% nail solution is a safe and effective new topical therapy for onychomycosis, which will fill a pressing need for more effective topical therapy in this disease. It is marketed under the brand name JUBLIA in the US and CLENAFIN in Japan.

Mechanism of action

Efinaconazole is an azole antifungal. Efinaconazole inhibits the fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the JUBLIA description, mechanism of action, dosage and administration, research and development activities in Onychomycosis.
• Elaborated details on JUBLIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JUBLIA research and development activity in Onychomycosis in detail across the United States, Europe, Japan and China.
• The report also covers the patents information with expiry timeline around JUBLIA.
• The report contains forecasted sales of JUBLIA for Onychomycosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Onychomycosis.
• The report also features the SWOT analysis with analyst views for JUBLIA in Onychomycosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JUBLIA Analytical Perspective by DelveInsight

In-depth JUBLIA Market Assessment

This report provides a detailed market assessment of JUBLIA in Onychomycosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan and China. This segment of the report provides forecasted sales data from 2023 to 2032.

JUBLIA Clinical Assessment

The report provides the clinical trials information of JUBLIA in Onychomycosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Onychomycosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JUBLIA dominance.
• Other emerging products for Onychomycosis are expected to give tough market competition to JUBLIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JUBLIA in Onychomycosis.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JUBLIA in Onychomycosis.

Key Questions

• What is the product type, route of administration and mechanism of action of JUBLIA?
• What is the clinical trial status of the study related to JUBLIA in Onychomycosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JUBLIA development?
• What are the key designations that have been granted to JUBLIA for Onychomycosis?
• What is the forecasted market scenario of JUBLIA for Onychomycosis?
• What are the forecasted sales of JUBLIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan and China?
• What are the other emerging products available in Onychomycosis and how are they giving competition to JUBLIA for Onychomycosis?
• Which are the late-stage emerging therapies under development for the treatment of Onychomycosis?